Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Moderate Buy” by Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $11.17.

A number of analysts have commented on the stock. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Jefferies Financial Group boosted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after buying an additional 19,095 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after acquiring an additional 356,352 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Compass Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares during the period. Barclays PLC lifted its position in shares of Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after purchasing an additional 70,200 shares during the period. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock opened at $3.90 on Tuesday. Compass Therapeutics has a 1-year low of $0.76 and a 1-year high of $4.07. The company has a market capitalization of $536.60 million, a P/E ratio of -10.54 and a beta of 1.17. The business’s fifty day moving average price is $2.12 and its two-hundred day moving average price is $1.74.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. On average, research analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.